MedTrace Logo

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

NCT05087745 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-17

No results posted yet for this study

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

  • Advanced Solid Tumor
  • Tumor Infiltrating Lymphocytes
  • Treatment Side Effects
  • Effects of Immunotherapy

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Sponsors & Collaborators

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-12-10
Completion
2025-12-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087745 on ClinicalTrials.gov